Cipla share price
NSE: CIPLAPharma & HealthcareDrug Manufacturers - Specialty & Generic
Cipla at a glance
Cipla (NSE: CIPLA) closed at ₹1,324.00 on 19 Oct 2026, down 0.12% on the day. With a market capitalisation of ₹1,06,959 Cr, it ranks 97th by market cap among the 4,183 NSE companies Pivot tracks (a large-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 27.5× trailing earnings, against a return on equity of 11.3% in FY26. Over the past year the share price has fallen 15.6%. Its 52-week range is ₹1,165.70 (2 Apr 2026) to ₹1,673.00 (23 Oct 2025); the last close is 20.9% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹7,077 Cr (+3.5% year on year) and net profit ₹787 Cr (−39.1%), on a consolidated basis. Promoters held 29.21% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹1,06,959 CrRank 97 on NSE
- P/E (trailing)
- 27.5×
- Price to book
- 2.87×FY26
- EPS (TTM)
- ₹41.74to Q1 FY27
- ROE
- 11.3%FY26
- ROCE
- 15.7%FY26
- Debt to equity
- 0.01FY26
- Net profit margin
- 13.7%FY26
- Book value / share
- ₹426.24FY26
- Dividend payout
- 33.3%FY26
- 52-week high
- ₹1,673.0023 Oct 2025
- 52-week low
- ₹1,165.702 Apr 2026
- 1-year return
- −15.6%
- RSI (14-day)
- 40.2
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.12% | +0.5% | −4.4% | −7.8% | −15.6% |
Cipla quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹6,961 Cr | ₹7,232 Cr | ₹6,598 Cr | ₹6,837 Cr | ₹7,447 Cr | ₹6,963 Cr | ₹6,464 Cr | ₹7,077 Cr |
| Revenue YoY | +5.6% | +9.5% | +8.5% | +3.2% | +7.0% | −3.7% | −2.0% | +3.5% |
| Net profit | ₹1,306 Cr | ₹1,584 Cr | ₹1,225 Cr | ₹1,292 Cr | ₹1,353 Cr | ₹675 Cr | ₹550 Cr | ₹787 Cr |
| Net profit YoY | +13.0% | +48.2% | +31.1% | +9.8% | +3.6% | −57.4% | −55.1% | −39.1% |
| Net margin | 18.8% | 21.9% | 18.6% | 18.9% | 18.2% | 9.7% | 8.5% | 11.1% |
| EPS | ₹16.13 | ₹19.61 | ₹15.13 | ₹16.07 | ₹16.73 | ₹8.37 | ₹6.87 | ₹9.77 |
Cipla financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹19,160 Cr | ₹21,763 Cr | ₹22,753 Cr | ₹25,774 Cr | ₹27,548 Cr | — |
| Operating profit | ₹3,290 Cr | ₹3,675 Cr | ₹4,221 Cr | ₹5,897 Cr | ₹6,821 Cr | — |
| Net profit | ₹2,401 Cr | ₹2,559 Cr | ₹2,835 Cr | ₹4,155 Cr | ₹5,291 Cr | — |
| EPS (₹) | ₹30.00 | ₹31.00 | ₹35.00 | ₹51.00 | ₹65.00 | — |
| Cash from operations | ₹3,755 Cr | ₹3,326 Cr | ₹3,238 Cr | ₹4,134 Cr | ₹5,005 Cr | — |
| Total debt | ₹1,203 Cr | ₹416 Cr | ₹0 Cr | ₹0 Cr | ₹12 Cr | ₹117 Cr |
| Shareholders' equity | ₹18,327 Cr | ₹20,842 Cr | ₹23,408 Cr | ₹26,706 Cr | ₹31,193 Cr | ₹34,432 Cr |
Cipla shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 29.20% | 29.19% | 29.21% | 29.21% | 29.21% | 29.21% |
| Foreign institutions | 26.28% | 25.24% | 24.55% | 23.93% | 22.56% | 20.21% |
| Domestic institutions | 28.15% | 29.26% | 30.25% | 30.72% | 31.97% | 34.63% |
| Non-institutions | 16.37% | 16.30% | 15.99% | 16.13% | 16.25% | 15.94% |
Cipla vs peers
The listed Pharma & Healthcare companies nearest to Cipla by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| LAURUSLABSLaurus Labs | ₹2,061.90 | +0.17% | +135.1% | ₹1,11,394 Cr | 124.8 | 8.0% |
| ZYDUSLIFEZydus Lifesciences | ₹1,111.50 | −1.23% | +11.9% | ₹1,10,873 Cr | 22.2 | 18.6% |
| APOLLOHOSPApollo Hospitals Enterprise | ₹7,695.00 | −1.75% | +0.1% | ₹1,10,642 Cr | 57 | 20.5% |
| CIPLACipla | ₹1,324.00 | −0.12% | −15.6% | ₹1,06,959 Cr | 27.5 | 11.3% |
| DRREDDYDr. Reddy's Laboratories | ₹1,241.20 | +0.89% | −1.8% | ₹1,03,600 Cr | 25 | 11.1% |
| AUROPHARMAAurobindo Pharma | ₹1,617.00 | −2.54% | +43.1% | ₹93,039 Cr | 26.8 | 9.2% |
| MANKINDMankind Pharma | ₹2,251.00 | −1.11% | −8.5% | ₹92,965 Cr | 48.7 | 11.7% |
Ask anything about Cipla
Pivot answers on the live chart with evidence you can check, and tests strategies against CIPLA's own history. Try: “Why has CIPLA moved over the last three months?” · “Backtest a 50-day moving-average crossover on CIPLA over five years” · “Compare CIPLA with LAURUSLABS on margins and valuation”
Frequently asked questions about Cipla
What is the share price of Cipla today?
Cipla (NSE: CIPLA) last closed at ₹1,324.00 on 19 Oct 2026. Its 52-week high is ₹1,673.00 and its 52-week low is ₹1,165.70.
What is the market cap of Cipla?
Cipla's market capitalisation is ₹1,06,959 Cr (₹1.07 lakh Cr) at the 19 Oct 2026 close, ranking 97th among the NSE companies Pivot tracks.
What is the P/E ratio of Cipla?
Cipla trades at a trailing P/E of 27.5. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 48.7.
What is the ROE and ROCE of Cipla?
Return on equity was 11.3% in FY26 and return on capital employed was 15.7% in FY26 (consolidated figures).
Is Cipla a debt-free company?
Cipla is close to debt-free: its debt-to-equity ratio was 0.01 in FY26.
What were Cipla's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Cipla reported revenue of ₹7,077 Cr, +3.5% year on year, and net profit of ₹787 Cr, −39.1% year on year.
How has Cipla stock performed over the last year?
Cipla's share price has fallen 15.6% over the past year, −7.8% over three months and −4.4% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Cipla?
As of 30 Jun 2026: promoters 29.21%, foreign institutions 20.21%, domestic institutions 34.63%, non-institutions 15.94%.
Who are Cipla's competitors?
The listed Pharma & Healthcare companies closest to Cipla by market cap are Laurus Labs, Zydus Lifesciences, Apollo Hospitals Enterprise, Dr. Reddy's Laboratories, Aurobindo Pharma and Mankind Pharma.
Is Cipla a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Cipla's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on CIPLA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with C · all NSE stocks · this page as text